Battalion Oil Corporation Announces Fourth Quarter 2023 Financial and Operating Results

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

HOUSTON, March 29, 2024 (GLOBE NEWSWIRE) — Battalion Oil Corporation (NYSE American: BATL, “Battalion” or the “Company”) today announced financial and operating results for the fourth quarter of 2023. Key Highlights Approximately 41,000 net acres, 91% HBP in three contiguous blocks across Ward, Winkler and Pecos Counties with substantial remaining location inventory Brought previously announced AGI project online in Q1 2024 treating over 20 MMcf/d Recommenced drilling operations in Monument Draw in Q4 2023 to execute a six well program Completed two wells in Q4 2023, brought online in Q1 2024 under budget with strong initial results Drilled two additional wells in Q1 2024, currently completing Commenced drilling operations on two additional wells in Q1 2024, currently drilling ahead Generated full year sales volumes of 13,784...

Power REIT Receives Audit Opinion with Going Concern Explanation

Written by Customer Service on March 29, 2024. Posted in Public Companies.

Old Bethpage, New York, March 29, 2024 (GLOBE NEWSWIRE) — Power REIT (NYSE-AMEX: PW and PW.PRA) (“Power REIT” or the “Trust”), today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 29, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Trust’s ability to continue as a going concern. See further discussion in footnote 3 to the Trust’s financial statements included in the Company’s Annual Report on Form 10-K. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing...

Titan Medical Reports Fiscal Year 2023 Results

Written by Customer Service on March 29, 2024. Posted in Public Companies.

TORONTO, Ontario, March 29, 2024 (GLOBE NEWSWIRE) — Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the fiscal year ended December 31, 2023. Recent Activities: On August 14, 2023, the Company announced the appointment of Dr. Daniel O’Brien, MD, MBA, Ph.D to its Board of Directors. On August 21, 2023, the Company announced a licensing agreement with Auris Health, Inc., a Johnson & Johnson MedTech Company. On October 18, 2023, the Company announced it had changed its auditor from BDO Canada LLP to MNP LLP. On March 18, 2024, the Company announced it has entered into a definitive amalgamation agreement (the “Definitive Agreement”) with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction (the “Transaction”). Under the terms of the Definitive...

Rackspace Technology Announces Increase to Late Exchange Consideration for Exchange Offer Relating to its 3.50% First-Priority Senior Secured Notes due 2028

Written by Customer Service on March 29, 2024. Posted in Public Companies.

SAN ANTONIO, March 29, 2024 (GLOBE NEWSWIRE) — Rackspace Technology® (NASDAQ: RXT) (“Rackspace” or the “Company”), a leading end-to-end hybrid, multicloud, and AI technology solutions company, today announced that its indirect subsidiary Rackspace Finance, LLC (the “New Issuer”) is amending the terms of its previously announced offer (the “Amendment”) to eligible holders in respect of any and all of the 3.50% First-Priority Senior Secured Notes due 2028 (the “Existing Secured Notes”) issued by Rackspace’s indirect subsidiary Rackspace Technology Global, Inc., to (i) (A) exchange certain of those Existing Secured Notes for new 3.50% FLSO Senior Secured Notes due 2028 (the “Exchange Notes”) issued by the New Issuer and (B) have purchased for cancellation certain of those Existing Secured Notes by the New Issuer for cash (collectively,...

FitLife Brands Announces Fourth Quarter and Full-Year 2023 Results and Investor Conference Call

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

OMAHA, NE, March 29, 2024 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife,” the “Company,” or “We”) (Nasdaq: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the year ended December 31, 2023. The Company’s improved financial performance during the quarter and for the full year was driven primarily by the acquisition of Mimi’s Rock Corp. (“MRC”), which closed on February 28, 2023. Highlights for the year ended December 31, 2023 include: Total revenue was $52.7 million, an increase of 83% compared to $28.8 million in the prior year. Online sales for the full year increased 309% to $33.4 million and represented 63% of total revenue compared to 28% in the prior year. Gross profit increased 78% to $21.4 million. Net income increased 20% to $5.3...

Weekly Report (March 22-28, 2024) on the First Tranch of Stellantis 2024 Share Buyback Program

Written by Customer Service on March 29, 2024. Posted in Public Companies.

Weekly Report (March 22-28, 2024) on the First Tranch of Stellantis 2024 Share Buyback Program AMSTERDAM, March 29, 2024 – Stellantis N.V. (“Stellantis” or the “Company”) announced today that pursuant to its First Tranche of the 2024 Share Buyback Program announced on February 28, 2024, covering up to €1 billion to be executed in the open market during the period between February 28, 2024 and June 5, 2024, it has repurchased the following common shares in the period between March 22 up to and including March 28, 2024: Date Number of Shares Repurchased Average Market Purchase Price in € per share Repurchased Volume in € (excluding fees) Venues 22-march-24 1 108 826 €26.9760 €29 911 719,75 MI 25-march-24 337 957 €27.0499 €9 141 692,09 MI 26-march-24 346 584 €26.6342 €9 230 992,66 MI Total 1 793 367 €26.9239 €48 284 404,50 Since...

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Written by Customer Service on March 29, 2024. Posted in Public Companies.

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on reversing aging in canines BALTIMORE, March 29, 2024 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and global animal health contract research, development and manufacturing organisation Argenta have agreed to begin a three to six-months study on the efficacy of Telomir-1 as a treatment for osteoarthritis and other diseases...

Table Trac, Inc. Reports Year End Results for 2023

Written by Customer Service on March 29, 2024. Posted in Public Companies.

MINNETONKA, Minn., March 29, 2024 (GLOBE NEWSWIRE) — Table Trac, Inc. (OTCQX: TBTC), a developer and provider of casino information and management systems that automate and monitor the operations of casinos announced financial results for the year ended December 31, 2023. The 10-K can be found @ http://www.sec.gov Year End Highlights Record $7 Million in Gross Profit Gross Margin percentage exceeds 74% Record reoccurring revenue of $4.9 Million a 42% increase over the prior year Table Trac declared and paid three quarterly dividends of $0.01/share. The CasinoTrac system was installed in thirteen locations during 2023. At the end of 2023, the Company had casino management systems, table games management systems and ancillary products installed with 110 casino operators in over 300 casinos worldwide. Table Trac established an office/showroom...

Avalo Reports 2023 Financial Results and Provides Business Updates

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 Expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end financial results for 2023. “We are very excited about the acquisition of AVTX-009 and concurrent financing of up to $185 million, $115.6 million of which we received upfront. The progress we made in 2023 to strengthen our balance sheet helped enable these transactions. I am proud of the team’s efforts and continued dedication in executing...

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 29, 2024. Posted in Earnings Releases And Operating Results.

– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – Topline data from planned interim analysis of ongoing Phase 2 study in chronic migraine are expected to be announced in Q2 2024; On track to announce top-line data from the full study in Q3 2024 – – Announced private placement agreements for $15 million in aggregate principal amount of senior secured convertible notes – IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for...

Day: March 29, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice